Loading...
Market
Verona Pharma's stock price increases by 20% or more by September 30, 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial news websites or stock exchange listings
Story
Verona Pharma's Ohtuvayre COPD Drug FDA-Approved at $2,950/Month
Jun 27, 2024, 09:27 AM
Verona Pharma, $VRNA, received FDA approval for its COPD drug, Ohtuvayre (ensifentrine), with a wholesale price of $2,950 per month. The drug is seen as a future blockbuster, targeting a significant unmet need in COPD treatment. The company is preparing for market launch with a strong sales and marketing strategy.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
